Vabon Special Precautions

Because VABON may cause fluid retention, the drug should be used with caution in patients who may be adversely affected by this condition such as those with seizure disorders, migraine, or cardiac or renal dysfunction.
Periodic evaluations of liver function should be performed in all patients receiving VABON, since the drug may cause hepatic dysfunction.
Semen should be evaluated for volume, viscosity, and sperm count and motility every 3 - 4 months during VABON therapy, especially in adolescents.
Patients should be carefully monitored for sign of virilization, since some adverse androgenic effects may not subside after discontinuance of the drug.
VABON has been associated with peliosis of the liver and benign or malignant hepatic adenoma, and such hepatic effects may not be apparent until complicated by acute, potentially life-threatening intra-abdominal hemorrhage; clinicians should be aware that such hepatotoxicity may develop during long-term administration of VABON.
Patients receiving VABON who develop signs and/or symptoms of pseudotumor cerebri (e.g., headache, nausea and vomiting, visual disturbances) should be examined for the presence of papilledema and informed to discontinue the drug immediately if any such manifestation is present; such patients should be referred to a neurologist for further evaluation and care.
Since substantial alterations in lipoprotein profiles (e.g., decreases in serum high-density lipoproteins, increases in serum low-density lipoproteins) have been reported in patients receiving VABON therapy, clinicians should be consider the potential increased risk of cardiovascular disease (e.g., coronary artery disease, atherosclerosis) versus the possible benefits of therapy.
The possibility of carcinoma of the breast should be excluded before initiating VABON therapy in patients with fibrocystic breast disease. Nodularity, pain and tenderness caused by fibrocystic breast disease may prevent recognition of underlying carcinoma before initiation of therapy. If any nodule persists or enlarges during VABON therapy, carcinoma should be considered and ruled out.